Back to Report Store Home

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

  • Published: Jul-2018
  • Report Code: GBIHC479MR
  • Report Format: pdf

Description

List of Tables

Table 1: Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018 13

Table 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016 37

Table 3: Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016 42

Table 4: Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016 43

Table 5: Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016 44

Table 6: Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016 44

Table 7: Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017 46

Table 8: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018 50

Table 9: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018 53

Table 10: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018 55

Table 11: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018 58

Table 12: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018 59

Table 13: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018 61

Table 14: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018 63

Table 15: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018 65

Table 16: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018 67

Table 17: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018 68

Table 18: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018 70

Table 19: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018 71

Table 20: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018 73

Table 21: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017–2024 110

Table 22: Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017–2024 120

Table 23: Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006–2018 143

Table 24: Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006–2018 159

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards